{
  "id": 2536243,
  "title": "PTC Therapeutics director Schmertzler disposes of $1.8m in stock",
  "url": "https://urgent.news/2026/08/22/ptc-therapeutics-director-schmertzler-disposes-of-1-8m-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-22T08:16:17.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/ptc-therapeutics-director-schmertzler-disposes-of-18m-in-stock-93CH-4872314"
  },
  "original_language": "en",
  "account": "Director Michael Schmertzler of PTC Therapeutics, Inc. (NASDAQ:PTCT) recently sold off a significant portion of his common stock worth about $1.8 million through multiple transactions between August 19 and August 20, 2026. The transaction prices ranged from $70.78 to $73.67 per share, with the stock currently priced at $69.82. Over the past year, the shares have surged by 38%, despite a brief decline from their 52-week high of $90.87. The sales involved 27,614 shares spread across various transactions at weighted average prices of $72.86, $73.67, $70.78, $71.88, and $72.92 per share. These dispositions were executed under a Rule 10b5-1 trading plan approved by Section Six Partners, L.P. on May 14, 2026. Schmertzler, who is a general and limited partner of the partnership, disclaims any beneficial ownership of the Section Six Partners' held shares, except for his financial stake. Although the company did not generate profits in the past year, analysts anticipate profitability this year with earnings expected at $2.00 per share. For a thorough assessment of PTCT’s financial condition and future potential, investors can refer to the detailed Pro Research Report, accessible exclusively on InvestingPro for PTC Therapeutics and 1,400+ other US equities.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}